文献速递前列腺癌

使用前列腺复发报告系统(PI-RR)评分的前列腺磁共振成像检测复发性前列腺癌:系统综述与Meta分析

Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2024-05-31

该系统综述与Meta分析评估PI-RR评分系统预测全腺体治疗后局部复发的诊断性能,检索至2023年12月,纳入6项研究共467例患者。PI-RR≥3的汇总敏感度为77.8%、特异度为80.2%;PI-RR≥4的汇总敏感度为61.9%、特异度为86.6%;观察者间一致性从一般到极好不等。

要点

  • PI-RR≥3的汇总敏感度为77.8%(95%CI 69.9-84.1%),特异度为80.2%(95%CI 58.2-92.2%)。
  • PI-RR≥4的汇总敏感度为61.9%(95%CI 35.6-82.7%),特异度为86.6%(95%CI 75.1-93.3%)。
  • 观察者间一致性从一般到极好不等,PI-RR≥3显示高敏感度和特异度。

核心结论

  • PI-RR在检测前列腺癌全腺体治疗后局部复发方面准确,观察者间一致性从一般到良好再到极好不等。
  • 总体而言,PI-RR cutoff≥3显示高敏感度和特异度。

研究设计与样本

  • 遵循PRISMA诊断试验准确性指南进行系统综述与Meta分析,检索相关数据库至2023年12月。
  • 纳入报告使用PI-RR评估前列腺癌复发MRI诊断性能的原始研究,共6项研究符合条件,涉及467例患者。
  • 使用随机效应模型估计汇总敏感度和特异度,分别采用PI-RR≥3和≥4两个阳性cutoff点评估诊断性能。

主要发现

  • 采用PI-RR≥3作为复发疾病cutoff(4项研究),敏感度为77.8%(95%CI 69.9-84.1%),特异度为80.2%(95%CI 58.2-92.2%)。
  • 采用PI-RR≥4作为cutoff(4项研究),敏感度为61.9%(95%CI 35.6-82.7%),特异度为86.6%(95%CI 75.1-93.3%)。
  • 总体观察者间一致性从一般到极好不等。

关键数值与推荐

  • PI-RR系统对全腺体治疗后前列腺癌的多参数MRI进行1至5分评分。
  • PI-RR≥3作为阳性cutoff时,汇总敏感度77.8%(95%CI 69.9-84.1%),特异度80.2%(95%CI 58.2-92.2%)。
  • PI-RR≥4作为阳性cutoff时,汇总敏感度61.9%(95%CI 35.6-82.7%),特异度86.6%(95%CI 75.1-93.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prostate Imaging for Recurrence Reporting (PI-RR) was introduced in 2021 to standardize the interpretation and reporting of multiparametric magnetic resonance imaging (MRI) for prostate cancer following whole-gland treatment. The system scores image on a scale from 1 to 5 and has shown promising results in single-center studies. The aim of our systematic review and meta-analysis was to assess the diagnostic performance of the PI-RR system in predicting the likelihood of local recurrence after whole-gland treatment. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for diagnostic test accuracy were followed. Relevant databases were searched up to December 2023. Primary studies met the eligibility criteria if they reported MRI diagnostic performance in prostate cancer recurrence using PI-RR. Diagnostic performance for MRI was assessed using two different cutoff points (≥3 or ≥4 for positivity according to the PI-RR system). A meta-analysis with a random-effects model was used to estimate pooled sensitivity and specificity values. KEY FINDINGS AND LIMITATIONS: Sixteen articles were identified for full-text reading, of which six were considered eligible, involving a total of 467 patients. Using a cutoff of PI-RR ≥3 (4 studies) for recurrent disease, the sensitivity was 77.8% (95% confidence interval [CI] 69.9-84.1%) and the specificity was 80.2% (95% CI 58.2-92.2%). Using a cutoff of PI-RR ≥4 (4 studies), the sensitivity was 61.9% (95% CI 35.6-82.7%) and the specificity was 86.6% (95% CI 75.1-93.3%). Overall, the inter-rater agreement varied from fair to excellent. CONCLUSIONS AND CLINICAL IMPLICATIONS: PI-RR is accurate in detecting local recurrence after whole-gland treatment for prostate cancer and shows fair-to-good to excellent inter-reader agreement. Overall, a PI-RR cutoff of ≥3 showed high sensitivity and specificity. PATIENT SUMMARY: We reviewed studies that reported on how good MRI scans using a scoring system called PI-RR were in detecting recurrence of prostate cancer. We found that this system shows good performance, with fair to excellent agreement between different radiologists.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mourato FA, Schmitt LG, Mariussi M, et al. Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 38824004. doi:10.1016/j.euo.2024.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。